drugset / Trial / NCT00319696
Bosentan in Digital Ulcers
NaSingle-groupOpen-labelTreatment
Summary
The aim of the study is to collect long-term efficacy, tolerability and safety data of bosentan in Systemic Sclerosis (SSc) patients suffering from ischemic digital ulcers (DUs).
Timeline
- Start
- 2004-07-08
- Primary completion
- 2009-01-22
- Completion
- 2009-01-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bosentan | Other / unclassified | 125 mg | Oral |
Indications
No indication recorded.